Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure (GRAIL)
A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study)
Sponsor: Fred Hutchinson Cancer Center
Listed as NCT01335932, this PHASE2 trial focuses on Acute Lung Injury and Acute Respiratory Distress Syndrome and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 12 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
May 2022 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Dec 2021 — May 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fred Hutchinson Cancer Center
- Genentech, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .